ECSP024402A - Anticuerpos para mcp-1 humana - Google Patents

Anticuerpos para mcp-1 humana

Info

Publication number
ECSP024402A
ECSP024402A EC2002004402A ECSP024402A ECSP024402A EC SP024402 A ECSP024402 A EC SP024402A EC 2002004402 A EC2002004402 A EC 2002004402A EC SP024402 A ECSP024402 A EC SP024402A EC SP024402 A ECSP024402 A EC SP024402A
Authority
EC
Ecuador
Prior art keywords
antibodies
mcp
human mcp
eotaxin
cdr2
Prior art date
Application number
EC2002004402A
Other languages
English (en)
Spanish (es)
Inventor
Peter Hiestand
Franco Padova
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP024402A publication Critical patent/ECSP024402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EC2002004402A 2000-06-30 2002-12-24 Anticuerpos para mcp-1 humana ECSP024402A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0016138.0A GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP024402A true ECSP024402A (es) 2003-02-06

Family

ID=9894801

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004402A ECSP024402A (es) 2000-06-30 2002-12-24 Anticuerpos para mcp-1 humana

Country Status (27)

Country Link
US (1) US20040047860A1 (cg-RX-API-DMAC10.html)
EP (1) EP1299421B1 (cg-RX-API-DMAC10.html)
JP (2) JP3920215B2 (cg-RX-API-DMAC10.html)
KR (1) KR100603899B1 (cg-RX-API-DMAC10.html)
CN (1) CN100486996C (cg-RX-API-DMAC10.html)
AR (1) AR046379A1 (cg-RX-API-DMAC10.html)
AT (1) ATE426616T1 (cg-RX-API-DMAC10.html)
AU (2) AU8390301A (cg-RX-API-DMAC10.html)
BR (1) BR0112086A (cg-RX-API-DMAC10.html)
CA (1) CA2412775A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20024256A3 (cg-RX-API-DMAC10.html)
DE (1) DE60138102D1 (cg-RX-API-DMAC10.html)
EC (1) ECSP024402A (cg-RX-API-DMAC10.html)
ES (1) ES2322643T3 (cg-RX-API-DMAC10.html)
GB (1) GB0016138D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0301477A3 (cg-RX-API-DMAC10.html)
IL (1) IL153721A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03000201A (cg-RX-API-DMAC10.html)
NO (1) NO20026063L (cg-RX-API-DMAC10.html)
NZ (1) NZ523195A (cg-RX-API-DMAC10.html)
PE (1) PE20020125A1 (cg-RX-API-DMAC10.html)
PL (1) PL207133B1 (cg-RX-API-DMAC10.html)
PT (1) PT1299421E (cg-RX-API-DMAC10.html)
RU (1) RU2314316C2 (cg-RX-API-DMAC10.html)
SK (1) SK18122002A3 (cg-RX-API-DMAC10.html)
WO (1) WO2002002640A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200300199B (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
EP2990394A1 (en) 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
CA2497804A1 (en) * 2002-09-12 2004-03-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-human mcp-1 antibody and fragment of said antibody
US20050232923A1 (en) * 2003-11-05 2005-10-20 Li Yan Methods and compositions for treating MCP-1 related pathologies
US20080299130A1 (en) * 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
TW200716174A (en) * 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
EP2041568A4 (en) * 2006-06-15 2009-08-12 CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
BRPI0718225A2 (pt) * 2006-10-05 2013-11-12 Centocor Ortho Biotech Inc Antagonistas de ccr2 para tratamento de fibrose
AU2007337983A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
US20100254992A1 (en) * 2007-06-29 2010-10-07 Anuk Das Anti-mcp-1 antibodies, compositions, methods and uses
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
CN102239180B (zh) 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
ES2533493T3 (es) 2008-08-20 2015-04-10 Probiodrug Ag Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato
CA2765949C (en) * 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
CN105051065A (zh) 2012-06-22 2015-11-11 索伦托治疗有限公司 与ccr2结合的抗原结合蛋白
EP3180026A4 (en) * 2014-08-15 2018-04-11 Pixarbio Corporation Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
CN105695495B (zh) * 2015-12-07 2020-02-18 中国石油大学(华东) 一种高活性人趋化因子的制备方法及用途
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
BR112022012010A2 (pt) * 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN119684454B (zh) * 2024-12-25 2025-09-12 武汉爱博泰克生物科技有限公司 针对人mcp-1蛋白的抗体、抗体对和试剂盒及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019552D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US7371825B2 (en) * 2004-06-30 2008-05-13 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
DE60138102D1 (de) 2009-05-07
AR046379A1 (es) 2005-12-07
SK18122002A3 (sk) 2003-06-03
PT1299421E (pt) 2009-06-26
RU2314316C2 (ru) 2008-01-10
CN1443199A (zh) 2003-09-17
MXPA03000201A (es) 2003-05-27
KR100603899B1 (ko) 2006-07-25
CA2412775A1 (en) 2002-01-10
KR20030014272A (ko) 2003-02-15
NZ523195A (en) 2005-09-30
NO20026063D0 (no) 2002-12-17
JP2007054079A (ja) 2007-03-08
AU8390301A (en) 2002-01-14
BR0112086A (pt) 2003-05-06
PE20020125A1 (es) 2002-03-12
WO2002002640A2 (en) 2002-01-10
US20040047860A1 (en) 2004-03-11
ZA200300199B (en) 2003-11-13
PL207133B1 (pl) 2010-11-30
EP1299421A2 (en) 2003-04-09
GB0016138D0 (en) 2000-08-23
WO2002002640A3 (en) 2002-05-16
CZ20024256A3 (cs) 2003-04-16
AU2001283903B2 (en) 2005-06-02
NO20026063L (no) 2003-02-27
IL153721A0 (en) 2003-07-06
HUP0301477A3 (en) 2005-11-28
PL359854A1 (en) 2004-09-06
ATE426616T1 (de) 2009-04-15
HUP0301477A2 (hu) 2003-08-28
JP2004502421A (ja) 2004-01-29
ES2322643T3 (es) 2009-06-24
CN100486996C (zh) 2009-05-13
JP3920215B2 (ja) 2007-05-30
EP1299421B1 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20026063D0 (no) Antistoffer mot human MCP-1
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
AR035581A1 (es) Anticuerpos para il-1beta humana
CL2008002923A1 (es) Anticuerpo monoclonal humano aislado porque se adhiere a mesotelina humana; composicion que comprende dicho anticuerpo; conjugado entre anticuerpo y agente terapeutico; molecula de acido nucleico que codifica el anticuerpo; uso para preparar un medicamento para tratar cancer.
GEP20074222B (en) Antibodies to cd40
PE20110797A1 (es) Anticuerpos anti mn
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
BRPI0513078B8 (pt) anticorpo igg que se liga a il-17 humana e composição líquida
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
CR9393A (es) Anticuerpos anti-ccr5 y usos de los mismos
EA200601752A1 (ru) Антимиостатиновые антитела
CY1115875T1 (el) Αντισωματα toy υποδοχεα 1 της ιντερφερονης αλφα και οι χρησεις αυτων
EA200801065A1 (ru) Антимиостатиновые антитела
CO6251370A2 (es) Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma
WO2005103081A3 (en) Human monoclonal antibodies against cd20
CL2010000790A1 (es) Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03).
PE20011219A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
BR0207151A (pt) Moléculas de aglutinação terapêuticas
WO2011139974A3 (en) Anti-pai-1 antibodies and methods of use thereof
ECSP066432A (es) Moléculas de enlace terapéuticas
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
DE60136527D1 (de) Antikörper gegen eotaxin und deren verwendung
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
AR046094A1 (es) Anticuerpos completamente humanos contra 4-1bb humano